Avertix Medical Inc.

Avertix Medical Inc. manufactures Guardian, the FDA-approved implantable cardiac alert system designed for early detection of acute coronary occlusion and myocardial infarction. Guardian is the world's first and only heart attack warning system approved by the FDA and represents a breakthrough device filling an unmet medical need in post-infarction patient management. The Guardian system provides continuous 24/7 monitoring and detection of abnormal changes in cardiac activity, including silent myocardial infarctions that would otherwise go undetected by symptom-based assessment. Upon detection of coronary occlusion onset, the device delivers real-time alerts to the patient through an emergency alarm comprising loud beeping, red flashing light, and chest vibration, prompting immediate emergency care activation. Key clinical benefits supported by peer-reviewed research include significant reduction in pre-hospital delay—Guardian patients arrived at the emergency department an average of 6.3 hours earlier than those relying on symptoms alone in the ALERTS study. This accelerated care is critical because approximately 45% of myocardial infarctions are silent or asymptomatic, and patients with prior myocardial infarction face a 20% elevated risk of recurrent events within five years, with substantially higher risk in diabetic, smoking, or multi-vessel coronary disease populations. The device targets secondary prevention in high-risk populations with prior myocardial infarction history and provides continuous peace of mind through automated detection, addressing the significant clinical and psychological burden associated with fear of unrecognized recurrent cardiac events. Clinical data demonstrate meaningful reduction in myocardial damage and improved outcomes through rapid intervention enabled by early warning detection.